IP Verse

Novel Pharmaceutical Composition Comprising Particles Comprising A Complex Of A Double-Stranded Polyribonucleotide And A Polyalkyleneimine - EP3319587

The patent EP3319587 was granted to Bioncotech Therapeutics on Aug 21, 2019. The application was originally filed on Nov 17, 2016 under application number EP16805990A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3319587

BIONCOTECH THERAPEUTICS
Application Number
EP16805990A
Filing Date
Nov 17, 2016
Status
Opposition Rejected
Apr 28, 2023
Grant Date
Aug 21, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TARGIMMUNE THERAPEUTICSMay 25, 2020LATSCHA SCHOLLHORN PARTNER -

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONCN102988303
DESCRIPTIONCN103599071
DESCRIPTIONUS2009117306
DESCRIPTIONUS2011003883
DESCRIPTIONWO2004045491
DESCRIPTIONWO2005102278
DESCRIPTIONWO2008057696
DESCRIPTIONWO2011003883
DESCRIPTIONWO2013040552
DESCRIPTIONWO2013063019
DESCRIPTIONWO2013087083
DESCRIPTIONWO2013164380
DESCRIPTIONWO2014057432
DESCRIPTIONWO2014165296
DESCRIPTIONWO2015067632
DESCRIPTIONWO2015173824
INTERNATIONAL-SEARCH-REPORTWO2011003883
INTERNATIONAL-SEARCH-REPORTWO2013087083
INTERNATIONAL-SEARCH-REPORTWO2015173824
OPPOSITIONEP2452189
OPPOSITIONWO2011003883

Non-Patent Literature (NPL) Citations (56) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AMMI R ET AL., PHARMACOL. THER., (2015), vol. 146, pages 1 20 - 31-
DESCRIPTION- AMOS SM ET AL., CANCER IMMUNOL. IMMUNOTHER., (2011), vol. 60, pages 671 - 83-
DESCRIPTION- BALD T ET AL., CANCER DISCOV., (2014), vol. 4, pages 674 - 87-
DESCRIPTION- BHOOPATHI P ET AL., CANCER RES., (2014), vol. 74, pages 6224 - 35-
DESCRIPTION- BILENSOY E, EXPERT OPIN. DRUG DELIV., (2010), vol. 7, pages 795 - 809-
DESCRIPTION- CHEN L ET AL., INT. J. NANOMED., (2013), vol. 8, pages 137 - 145-
DESCRIPTION- CHIBA Y ET AL., PLOSONE, (2013), vol. 8, page E76159-
DESCRIPTION- COBALEDA-SILES M ET AL., SMALL., (2014), vol. 10, pages 5054 - 67-
DESCRIPTION- DUEWELL P ET AL., ONCOLMMUNOL., (2015), vol. 4, no. 10, page E1029698-
DESCRIPTION- EWEL C ET AL., CANCER RES., (1992), vol. 52, pages 3005 - 10-
DESCRIPTION- FUJIMURA T ET AL., EUR. J. IMMUNOL., (2006), vol. 36, pages 3371 - 80-
DESCRIPTION- GALLUZZI L ET AL., ONCOTARGET, (2014), vol. 5, pages 12472 - 508-
DESCRIPTION- GARCIA-PASCUAL C; GOMEZ R, J. ENDOMETR., (2013), vol. 5, no. 1-
DESCRIPTION- GERMERSHAUS O; NULTSCH K, ASI J PHARM SCI., (2015), vol. 10, pages 159 - 175-
DESCRIPTION- GUPTA S ET AL., TUMOR BIOL., (2016), vol. 37, pages 12089 - 12102-
DESCRIPTION- HAFNER A ET AL., ADVANCED DRUG DELIVERY REV., (2013), vol. 65, no. 10, pages 1386 - 1399-
DESCRIPTION- HO V ET AL., ONCOTARGET., (2015), vol. 6, pages 27252 - 27266-
DESCRIPTION- ISLAM M ET AL., JOURNAL OF CONTROLLED RELEASE, (2014), vol. 193, pages 74 - 89-
DESCRIPTION- KABILOVA T ET AL., BMC CANCER., (2014), vol. 14, page 338-
DESCRIPTION- KEIR M ET AL., ANNU. REV. IMMUNOL., (2008), vol. 26, pages 677 - 704-
DESCRIPTION- KUBLER K ET AL., EUR. J. IMMUNOL., (2011), vol. 41, pages 3028 - 39-
DESCRIPTION- KUROSAKI T ET AL., BIOMATERIALS, (2009), vol. 30, pages 2846 - 2853-
DESCRIPTION- LE U ET AL., CANC. BIOL. THER., (2008), vol. 7, pages 440 - 447-
DESCRIPTION- LE U ET AL., RADIOTHER. ONCOL., (2009), vol. 90, pages 273 - 279-
DESCRIPTION- LEVITZKI A, FRONT. ONCOL., (2012), vol. 2, page 4-
DESCRIPTION- MATIJEVIC T ET AL., CHEMOTHERAPY, (2011), vol. 57, pages 460 - 7-
DESCRIPTION- MCBAIN S ET AL., J. MATER. CHEM., (2007), vol. 17, pages 2561 - 2565-
DESCRIPTION- NAGATO T; CELIS E, ONCOIMMUNOLOGY, (2014), vol. 3, page E28440-
DESCRIPTION- "Nano-Oncologicals", POZUELO-RUBIO M ET AL., Adv. Del. Sci. Tech., SPRINGER, (2014), pages 453 - 470-
DESCRIPTION- OHASHI T ET AL., INT. J. CANCER, (2013), vol. 133, pages 1107 - 18-
DESCRIPTION- PALCHETTI S ET AL., RSC ADV., (2013), vol. 3, pages 24597 - 24604-
DESCRIPTION- PERROT I ET AL., J. IMMUNOL., (2010), vol. 185, pages 2080 - 2088-
DESCRIPTION- SAHEKI A ET AL., INT. J. PHARM., (2011), vol. 406, pages 117 - 21-
DESCRIPTION- SAJADIAN A ET AL., ARCH. VIROL., (2014), vol. 159, pages 1951 - 1960-
DESCRIPTION- SCHAFFERT D ET AL., PHARM. RES., (2011), vol. 28, pages 731 - 741-
DESCRIPTION- SHABANI M ET AL., AVICENNA J. MED. BIOTECH., (2010), vol. 2, pages 123 - 130-
DESCRIPTION- STORZ U, MABS, (2011), vol. 3, pages 310 - 7-
DESCRIPTION- SZABO A ET AL., MELANOMA RES., (2012), vol. 22, pages 351 - 361-
DESCRIPTION- TAURA M ET AL., CANCER SCI., (2010), vol. 101, pages 1610 - 7-
DESCRIPTION- TORMO D ET AL., CANCER CELL, (2009), vol. 16, pages 103 - 114-
DESCRIPTION- TUTIN-MOEAVIN I ET AL., ORG & BIOMOL CHEM., (2015), vol. 13, pages 9005 - 9011-
DESCRIPTION- VACCHELLI E ET AL., ONCOIMMUNOLOGY, (2013), vol. 2, page E25396,E23510,E25595-
DESCRIPTION- VAN DER JEUGHT K ET AL., ONCOTARGET, (2015), vol. 6, pages 1359 - 81-
DESCRIPTION- VEGA-LETTER A ET AL., STEM CELL RES. & THER., (2016), vol. 7, page 150-
DESCRIPTION- YOSHINO H; KASHIWAKURA I, BLOOD, (2013), vol. 122, page 4721-
DESCRIPTION- YU L ET AL., IMMUNOL CELL BIOL., (2016), vol. 94, pages 875 - 885-
DESCRIPTION- ZHANG Y ET AL., CANCER LETT., (2014), vol. 355, pages 76 - 84-
DESCRIPTION- ZHOU Y ET AL., INNATE IMMUN., (2013), vol. 19, pages 184 - 192-
INTERNATIONAL-SEARCH-REPORT- DAVID SCHAFFERT ET AL, "Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier", PHARMACEUTICAL RESEARCH, US, (20110401), vol. 28, no. 4, doi:10.1007/s11095-010-0225-4, ISSN 0724-8741, pages 731 - 741, XP055236351 [X] 1-7,9,10,13,17-20 * abstract * * page 732, column r, paragraph l - page 733, column r, paragraph 4 * * page 734, column l, paragraph l - page 734, column r, paragraph 1 * * page 735; table 1 * * page 737, column r, paragraph 3 - page 739, column l, paragraph 1 * * page 740, column l, paragraph 2 * [I] 8,11,12,14-16,21-25
INTERNATIONAL-SEARCH-REPORT- KUROSAKI T ET AL, "Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 30, no. 14, doi:10.1016/J.BIOMATERIALS.2009.01.055, ISSN 0142-9612, (20090501), pages 2846 - 2853, (20090220), XP025970952 [A] 1-25 * page 2846, column l, paragraph 1 * * page 2847, column l, paragraphs 2,3 * * page 2847; figure 1; table 1 *
OPPOSITION- Sabine Boeckle, Wagner, E., Ogris, M., "C- versus N-terminally linked melittin-polyethylenimine conjugates; the site of linkage strongly influences activity of DNA polyplexes", The Journal of Gene Medicine, (20050101), vol. 7, pages 1335 - 1347, XP055743586
OPPOSITION- Mercedes Pozuelo-Rubio, Damià Tormo Carulla, Andrés P. Gagete, María Soengas, "BO-110, a dsRNA-Based Anticancer Agent", Nano-Oncologicals : New Targeting and Delivery Approaches, Cham, Springer International Publishing, (20140101), pages 453 - 470, doi:10.1007/978-3-319-08084-0_16, XP009510970
OPPOSITION- David Schaffert, Melinda Kiss, Wolfgang R�dl, Alexei Shir, Alexander Levitzki, Manfred Ogris, Ernst Wagner, "Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier", Pharmaceutical Research, US, (20110401), vol. 28, no. 4, doi:10.1007/s11095-010-0225-4, ISSN 0724-8741, pages 731 - 741, XP055236351
OPPOSITION- TORMO DAMIA ET AL, "Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells", CANCER CELL, CELL PRESS, US, US, (20090804), vol. 16, no. 2, doi:10.1016/J.CCR.2009.07.004, ISSN 1535-6108, pages 103 - 114, XP002597296
OPPOSITION- García-Pascual Carmen Maria; Martínez Jessica; Calvo Paula; Ferrero Hortensia; Villanueva Ana; Pozuelo-Rubio Mercedes; Soengas Marisol; Tormo Damiá; Simón Carlos; Pellicer Antonio; Gómez Raúl, "Evaluation of the potential therapeutic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of endometriosis", Fertility and Sterility, NL, (20150818), vol. 104, no. 5, doi:10.1016/j.fertnstert.2015.07.1147, ISSN 0015-0282, pages 1310 - 1318, XP029289587
OPPOSITION- P. Bhoopathi, B. A. Quinn, Q. Gui, X.-N. Shen, S. R. Grossman, S. K. Das, D. Sarkar, P. B. Fisher, L. Emdad, "Pancreatic Cancer-Specific Cell Death Induced In Vivo by Cytoplasmic-Delivered Polyinosine-Polycytidylic Acid", Cancer research, American Association for Cancer Research, (20141101), vol. 74, no. 21, doi:10.1158/0008-5472.CAN-14-0819, ISSN 0008-5472, pages 6224 - 6235, XP055611853

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents